By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Moderna Therapeutics, Inc. 

320 Bent Street

Cambridge  Massachusetts  02141  U.S.A.
Phone: 617-714-6500 Fax: 617-583-1998


SEARCH JOBS

At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.

We have a clear mission to propel the field of mRNA science forward and deliver new medicines to patients and a unique vision for how to achieve this mission.

Our Mission: Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.

Our Vision: Unlock the potential of mRNA Therapeutics™ by establishing an ecosystem of teams and partners that will work together to develop the broadest possible array of drugs, across diverse therapeutic areas and routes of administration, for serious diseases that are not treatable today.


Key Statistics


Email: info@modernatx.com
Ownership: Private

Web Site: Moderna
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
Ex-Novartis AG (NVS) Exec to Lead Moderna's Manufacturing and Operations Scale-Up 8/3/2017 6:22:00 AM
Moncef M. Slaoui, Ph.D. Joins Moderna’s Board Of Directors 7/27/2017 8:31:32 AM
Moderna Provides Update On mRNA Rare Disease R&D Strategy 7/27/2017 6:42:45 AM
Alexion (ALXN) Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint (BPMC) and Arbutus Biopharma (ABUS) 7/27/2017 5:58:27 AM
Publication In Cell Demonstrates Moderna’s Zika Mrna Vaccine Prevents In Utero Transmission Of Zika Virus In Mice, Protects Against Zika-Related Congenital Damage 7/13/2017 10:59:26 AM
A Look At The Beef Between Arbutus Biopharma (ABUS) And Biotech Unicorn Moderna 5/17/2017 5:44:02 AM
Melissa J. Moore, Ph.D., Chief Scientific Officer, mRNA Research Platform At Moderna, Elected To National Academy of Sciences 5/3/2017 8:42:55 AM
Biotech Unicorn Moderna's Vaccine Performs Well in First Human Trial 4/28/2017 5:52:12 AM
Moderna Announces Positive Interim Phase I Clinical Data Demonstrating First mRNA Vaccine Candidate, mRNA-1440, Induces High Levels Of Immunogenicity 4/27/2017 11:22:15 AM
Moderna Appoints Israel Ruiz To Its Board Of Directors 2/22/2017 6:26:03 AM
12345678
//-->